Qualigen Therapeutics (NASDAQ:AIXC) Trading Down 3.4% – What’s Next?

Shares of Qualigen Therapeutics, Inc. (NASDAQ:AIXC) traded down 3.4% during trading on Wednesday . The company traded as low as $0.7583 and last traded at $0.7711. 17,246 shares were traded during mid-day trading, a decline of 54% from the average session volume of 37,690 shares. The stock had previously closed at $0.7980.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Qualigen Therapeutics in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Qualigen Therapeutics Trading Down 0.4%

The stock has a market capitalization of $16.64 million, a price-to-earnings ratio of -0.13 and a beta of 0.53. The stock has a 50 day simple moving average of $1.06.

Qualigen Therapeutics (NASDAQ:AIXC) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.21) earnings per share (EPS) for the quarter.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.